合并用药对溃疡性结肠炎生物制剂和小分子药物治疗有效性与安全性无影响
该研究通过10项溃疡性结肠炎先进疗法临床试验的个体患者数据汇总分析,纳入6044例患者,评估基线合并使用糖皮质激素、免疫调节剂、美沙拉秦等药物是否改变干预措施对疗效和安全性的影响。结果显示多数合并用药对临床缓解无显著影响,但合并免疫调节剂与较低临床缓解可能性相关,尤其在使用非抗肿瘤坏死因子拮抗剂时。
要点
- 合并使用糖皮质激素、美沙拉秦、质子泵抑制剂等对临床缓解无显著影响。
- 合并免疫调节剂与较低临床缓解可能性相关(RRR 0.73),尤其非抗TNF拮抗剂。
- 基线合并多种常用药物不影响先进疗法治疗溃疡性结肠炎的安全性或有效性。
核心结论
- 在溃疡性结肠炎先进疗法临床试验中,基线合并使用多种常用药物类别不影响治疗有效性或安全性。
研究设计与样本
- 对10项中重度溃疡性结肠炎先进疗法临床试验进行个体患者数据汇总分析,共纳入6044例患者(干预组4280例,安慰剂组1764例),采用改良泊松回归模型评估合并用药对疗效和安全性的影响。
主要发现
- 合并使用糖皮质激素者占47%,免疫调节剂占28%,美沙拉秦占68%,质子泵抑制剂占14%,组胺受体拮抗剂占2%,阿片类药物占7%,抗抑郁药占6%,抗生素占5%。
- 合并使用糖皮质激素对临床缓解的RRR为0.81(95%CI 0.63-1.06),美沙拉秦为1.04(0.78-1.39),质子泵抑制剂为0.87(0.61-1.22),组胺受体拮抗剂为1.72(0.97-14.29),阿片类药物为0.90(0.54-1.49),抗抑郁药为1.02(0.57-1.83),抗生素为0.72(0.44-1.16)。
- 合并使用免疫调节剂与较低临床缓解可能性相关(RRR 0.73,95%CI 0.55-0.97),尤其在使用非抗肿瘤坏死因子拮抗剂时。
临床怎么用
- 这些发现直接为监管临床试验设计中对基线合并用药的管理提供了信息。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Although participants with inflammatory bowel diseases in clinical trials of biologics and small molecule drugs (henceforth, advanced therapies) frequently receive several medications concomitantly, it is unclear how they modify treatment effect. METHODS: Through an individual patient data pooled analysis of 10 clinical trials of advanced therapies for moderate-to-severe ulcerative colitis, we assessed whether concomitant exposure to corticosteroids, immunomodulators, mesalamine, proton pump inhibitors, histamine receptor antagonists, opiates, antidepressants, and antibiotics modified the effect of the intervention on treatment efficacy and safety outcomes, using modified Poisson regression model. RESULTS: Of 6044 patients (4280 receiving intervention, 1764 receiving placebo), several received concomitant corticosteroids (47%), immunomodulators (28%), mesalamine (68%), proton pump inhibitors (14%), histamine receptor antagonists (2%), opiates (7%), antidepressants (6%), and/or antibiotics (5%). After adjusting for confounders and examining treatment efficacy of intervention versus placebo, we observed no impact of concomitant exposure to corticosteroids (ratio of relative risk of drug vs placebo with vs without concomitant exposure: ratio of risk ratio [RRR], 0.81 [95% confidence interval, 0.63-1.06]), mesalamine (RRR, 1.04 [0.78-1.39]), proton pump inhibitors (RRR, 0.87 [0.61-1.22]), histamine receptor antagonists (RRR, 1.72 [0.97-14.29]), opiates (RRR, 0.90 [0.54-1.49]), antidepressants (RRR, 1.02 [0.57-1.83]), and antibiotics (RRR, 0.72 [0.44-1.16]) on likelihood of clinical remission. Concomitant exposure to immunomodulators was associated with lower likelihood of achieving clinical remission (RRR, 0.73 [0.55-0.97]), particularly with non-tumor necrosis factor antagonists. CONCLUSIONS: In clinical trials of advanced therapies for ulcerative colitis, baseline concomitant exposure to multiple commonly used class of medications does not impact treatment efficacy or safety. These findings directly inform design of regulatory clinical trials with respect to managing concomitant medications at baseline.
引用
- Ahuja D, Zou G, Solitano V, et al. No Impact of Concomitant Medications on Efficacy and Safety of Biologics and Small Molecules for Ulcerative Colitis. Clin Gastroenterol Hepatol. 2024. PMID: 39395572. doi:10.1016/j.cgh.2024.08.040
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。